inclusion body


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.
Related to inclusion body: inclusion body disease

inclusion body

n.
An abnormal structure in a cell nucleus or cytoplasm having characteristic staining properties and usually composed of protein, occurring primarily in infectious diseases, especially viral infections such as rabies.

inclusion body

A generic term for a circumscribed mass of intracellular or intranuclear material, which is often “foreign” to the cell or nucleus.

Examples
Metal (e.g., lead, mercury); viral particles (e.g., herpes, CMV); metabolically inactive materials (e.g., ceroid, Mallory bodies).

inclusion body

  1. a body present in the nuclei or cytoplasm of cells infected by viruses or other intracellular parasites.
  2. an insoluble protein aggregate that may form a crystalline structure inside host cells. An inclusion body may form as a result of overproduction of recombinant or normal protein in an overexpression system (see GENE EXPRESSION).
References in periodicals archive ?
Clinical and Pathological Findings in Falcons Affected With Inclusion Body Herpesvirus Hepatitis
Preparation and evaluation of lyophilized live attenuated vaccine of inclusion body hepatitis hydro-pericardium syndrome (IBH-HPS) against challenge in broiler chickens.
Greenberg, "Evaluation and construction of diagnostic criteria for inclusion body myositis," Neurology, vol.
* The report assesses Inclusion Body Myositis (IBM) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
Inclusion body myositis: diagnosis, pathogenesis, and tieatinent options.
The renaturation process was significant, and it is possible that IEC could be very useful in refolding inclusion body proteins on a large scale.
The potentially high costs for development of an inclusion body process are highlighted by myriad parameters that must be optimized.
Based on clinical and histopathological features, they can be divided into polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM).
Three entities are usually associated with FTLD-FUS: basophilic inclusion body disease, neuronal intermediate filament inclusion disease, and atypical FTLD with ubiquitinated inclusions.
Last month Novartis AG announced that the FDA granted breakthrough therapy designation to BYM338 for sporadic inclusion body myositis (sIBM).